A recent paper gives us a preview of precision medicine, and the breadth of the undertaking should humble us. Consider it medicine's moonshot.
Dr. Henry Miller, a former FDA deputy commissioner, used to be a big fan of the New York Times' coverage of science and medicine. But no longer. He takes issue with an editorial that accuses the agency of reducing its scrutiny of new drugs. Dr. Miller explains why the Times is off-base: the development of precision medicine.
A new paper shares a different -- and perhaps, a better way -- of describing the outcome of care. It's more than alive or dead; it's about how much better patients are living their lives.
The siren song of precision medicine is lost in the translation, from the laboratory to the bedside. Two studies suggest that precision medicine is more an aspirational term than reality.
Does Geisinger Health System's latest pitch, to offer DNA sequencing as part of routine testing at the primary care visit, promise more than it can deliver?